section name header

Pronunciation

kee-TOE-role-ak

Classifications

Therapeutic Classification: nonopioid analgesics

Pharmacologic Classification: nonsteroidal anti inflammatory drugs nsaids

Indications

BEERS REMS


Action

  • Inhibits prostaglandin synthesis, producing peripherally mediated analgesia.
  • Also has antipyretic and anti-inflammatory properties.
Therapeutic effects:
  • Decreased pain.

Pharmacokinetics

Absorption: Rapidly and completely absorbed following all routes of administration.

Distribution: Well distributed to tissues.

Protein Binding: 99%.

Metabolism/Excretion: Primarily metabolized by the liver. Primarily by the kidneys (92%); 6% excreted in feces.

Half-Life: 4.5 hr (range 3.8–6.3 hr; in geriatric patients and patients with impaired renal function).

Time/Action Profile

(analgesic effects)

ROUTEONSETPEAKDURATION
POunknown2–3 hr4–6 hr or longer
IM, IV10 min1–2 hr6 hr or longer
INunknownunknown6–8 hr or longer





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: edema, HF, MI

Derm: DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), EXFOLIATIVE DERMATITIS, pruritus, purpura, STEVENS-JOHNSON SYNDROME, sweating, TOXIC EPIDERMAL NECROLYSIS, urticaria

EENT: lacrimation (spray), nasal discomfort (spray), throat irritation (spray)

F and E: hyperkalemia

GI: liver enzymes, abdominal pain, abnormal taste, diarrhea, dry mouth, dyspepsia, GI BLEEDING, nausea

GU: oliguria, renal toxicity, urinary frequency

Hemat: prolonged bleeding time

Local: injection site pain

Neuro: drowsiness, abnormal thinking, dizziness, euphoria, headache, paresthesia, STROKE

Resp: asthma, dyspnea

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS)

Interactions

Drug-drug:

Drug-Natural Products:

Route/Dosage

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

IV Administration:

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Sprix, Toradol

Canadian Brand Names

Toradol